NOPIOD Trademark

Trademark Overview


On Friday, March 1, 2024, a trademark application was filed for NOPIOD with the United States Patent and Trademark Office. The USPTO has given the NOPIOD trademark a serial number of 98429316. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Tuesday, September 17, 2024. This trademark is owned by Asclemed USA, Inc.. The NOPIOD trademark is filed in the Pharmaceutical Products category with the following description:

prescription medicines and non-prescription medicines, namely, pharmaceutical preparations in oral capsules
nopiod

General Information


Serial Number98429316
Word MarkNOPIOD
Filing DateFriday, March 1, 2024
Status638 - NEW APPLICATION - ASSIGNED TO EXAMINER
Status DateTuesday, September 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Servicesprescription medicines and non-prescription medicines, namely, pharmaceutical preparations in oral capsules

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 1, 2024
Primary Code005
First Use Anywhere DateWednesday, November 2, 2022
First Use In Commerce DateWednesday, November 2, 2022

Trademark Owner History


Party NameAsclemed USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTorrance, CA 90501

Trademark Events


Event DateEvent Description
Friday, March 1, 2024NEW APPLICATION ENTERED
Friday, March 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 17, 2024ASSIGNED TO EXAMINER